Skip to main content
Erschienen in: Nuclear Medicine and Molecular Imaging 4/2016

13.07.2016 | Original Article

Intra-patient Variability of FDG Standardized Uptake Values in Mediastinal Blood Pool, Liver, and Myocardium during R-CHOP Chemotherapy in Patients with Diffuse Large B-cell Lymphoma

verfasst von: Soo Jeong Kim, Hyun Kyung Yi, Chae Hong Lim, Young Seok Cho, Joon Young Choi, Yearn Seong Choe, Kyung-Han Lee, Byung-Tae Kim, Seung Hwan Moon

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

18F-fluorodeoxyglucose (FDG) PET/CT is useful for staging and evaluating treatment response in patients with diffuse large B-cell lymphoma (DLBCL). A five-point scale model using the mediastinal blood pool (MBP) and liver as references is a recommended method for interpreting treatment response. We evaluated the variability in standardized uptake values (SUVs) of the MBP, liver, and myocardium during chemotherapy in patients with DLBCL.

Methods

We analyzed 60 patients with DLBCL who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) treatment and underwent baseline, interim, and final FDG PET/CT scans. The FDG uptakes of lymphoma lesions, MBP, liver, and myocardium were assessed, and changes in the MBP and liver SUV and possible associated factors were evaluated.

Results

The SUV of the liver did not change significantly during the chemotherapy. However, the SUVmean of MBP showed a significant change though the difference was small (p = 0.019). SUVmean of MBP and liver at baseline and interim scans was significantly lower in patients with advanced Ann Arbor stage on diagnosis. The SUVmean of the MBP and liver was negatively correlated with the volumetric index of lymphoma lesions in baseline scans (r = -0.547, p < 0.001; r = -0.502, p < 0.001). Positive myocardial FDG uptake was more frequently observed in interim and final scans than in the baseline scan, but there was no significant association between the MBP and liver uptake and myocardial uptake.

Conclusions

The SUV of the liver was not significantly changed during R-CHOP chemotherapy in patients with DLBCL, whereas the MBP SUV of the interim scan decreased slightly. However, the SUV of the reference organs may be affected by tumor burden, and this should be considered when assessing follow-up scans. Although myocardial FDG uptake was more frequently observed after R-CHOP chemotherapy, it did not affect the SUV of the MBP and liver.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013;87:146–71.CrossRefPubMed Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013;87:146–71.CrossRefPubMed
3.
Zurück zum Zitat Ceriani L, Suriano S, Ruberto T, Zucca E, Giovanella L. 18F-FDG uptake changes in liver and mediastinum during chemotherapy in patients with diffuse large B-cell lymphoma. Clin Nucl Med. 2012;37:949–52.CrossRefPubMed Ceriani L, Suriano S, Ruberto T, Zucca E, Giovanella L. 18F-FDG uptake changes in liver and mediastinum during chemotherapy in patients with diffuse large B-cell lymphoma. Clin Nucl Med. 2012;37:949–52.CrossRefPubMed
4.
Zurück zum Zitat Chiaravalloti A, Danieli R, Abbatiello P, Di Pietro B, Travascio L, Cantonetti M, et al. Factors affecting intrapatient liver and mediastinal blood pool (1)(8)F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1123–32.PubMed Chiaravalloti A, Danieli R, Abbatiello P, Di Pietro B, Travascio L, Cantonetti M, et al. Factors affecting intrapatient liver and mediastinal blood pool (1)(8)F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1123–32.PubMed
5.
Zurück zum Zitat Kaya B, Dostbil Z, Ismailoglu M, Tasdemir B. Sahin O. Clin Imaging: Effect of R-CHOP chemotherapy on liver and mediastinal blood pool F-FDG standardized uptake values in patients with non-Hodgkin’s lymphoma; 2015. Kaya B, Dostbil Z, Ismailoglu M, Tasdemir B. Sahin O. Clin Imaging: Effect of R-CHOP chemotherapy on liver and mediastinal blood pool F-FDG standardized uptake values in patients with non-Hodgkin’s lymphoma; 2015.
6.
Zurück zum Zitat Lobert P, Brown RK, Dvorak RA, Corbett JR, Kazerooni EA, Wong KK. Spectrum of physiological and pathological cardiac and pericardial uptake of FDG in oncology PET-CT. Clin Radiol. 2013;68:e59–71.CrossRefPubMed Lobert P, Brown RK, Dvorak RA, Corbett JR, Kazerooni EA, Wong KK. Spectrum of physiological and pathological cardiac and pericardial uptake of FDG in oncology PET-CT. Clin Radiol. 2013;68:e59–71.CrossRefPubMed
7.
Zurück zum Zitat Israel O, Weiler-Sagie M, Rispler S, Bar-Shalom R, Frenkel A, Keidar Z, et al. PET/CT quantitation of the effect of patient-related factors on cardiac 18F-FDG uptake. J Nucl Med. 2007;48:234–9.PubMed Israel O, Weiler-Sagie M, Rispler S, Bar-Shalom R, Frenkel A, Keidar Z, et al. PET/CT quantitation of the effect of patient-related factors on cardiac 18F-FDG uptake. J Nucl Med. 2007;48:234–9.PubMed
8.
Zurück zum Zitat Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis. 2010;53:105–13.CrossRefPubMedPubMedCentral Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis. 2010;53:105–13.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Limat S, Daguindau E, Cahn JY, Nerich V, Brion A, Perrin S, et al. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin’s lymphoma. J Clin Pharm Ther. 2014;39:168–74.CrossRefPubMed Limat S, Daguindau E, Cahn JY, Nerich V, Brion A, Perrin S, et al. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin’s lymphoma. J Clin Pharm Ther. 2014;39:168–74.CrossRefPubMed
10.
Zurück zum Zitat Freudenberg LS, Antoch G, Schutt P, Beyer T, Jentzen W, Muller SP, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging. 2004;31:325–9.CrossRefPubMed Freudenberg LS, Antoch G, Schutt P, Beyer T, Jentzen W, Muller SP, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging. 2004;31:325–9.CrossRefPubMed
11.
Zurück zum Zitat Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–58.CrossRefPubMedPubMedCentral Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–58.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Lin CY, Ding HJ, Lin T, Lin CC, Kuo TH, Kao CH. Positive correlation between serum liver enzyme levels and standard uptake values of liver on FDG-PET. Clin Imaging. 2010;34:109–12.CrossRefPubMed Lin CY, Ding HJ, Lin T, Lin CC, Kuo TH, Kao CH. Positive correlation between serum liver enzyme levels and standard uptake values of liver on FDG-PET. Clin Imaging. 2010;34:109–12.CrossRefPubMed
13.
Zurück zum Zitat Pak K, Kim SJ, Kim IJ, Kim K, Kim H, Kim SJ. Hepatic FDG uptake is not associated with hepatic steatosis but with visceral fat volume in cancer screening. Nucl Med Mol Imaging. 2012;46:176–81.CrossRefPubMedPubMedCentral Pak K, Kim SJ, Kim IJ, Kim K, Kim H, Kim SJ. Hepatic FDG uptake is not associated with hepatic steatosis but with visceral fat volume in cancer screening. Nucl Med Mol Imaging. 2012;46:176–81.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Groheux D, Delord M, Rubello D, Colletti PM, Nguyen ML, Hindie E. Variation of liver SUV on (18)FDG-PET/CT studies in women with breast cancer. Clin Nucl Med. 2013;38:422–5.CrossRefPubMed Groheux D, Delord M, Rubello D, Colletti PM, Nguyen ML, Hindie E. Variation of liver SUV on (18)FDG-PET/CT studies in women with breast cancer. Clin Nucl Med. 2013;38:422–5.CrossRefPubMed
15.
Zurück zum Zitat Borde C, Kand P, Basu S. Enhanced myocardial fluorodeoxyglucose uptake following Adriamycin-based therapy: Evidence of early chemotherapeutic cardiotoxicity? World J Radiol. 2012;4:220–3.CrossRefPubMedPubMedCentral Borde C, Kand P, Basu S. Enhanced myocardial fluorodeoxyglucose uptake following Adriamycin-based therapy: Evidence of early chemotherapeutic cardiotoxicity? World J Radiol. 2012;4:220–3.CrossRefPubMedPubMedCentral
Metadaten
Titel
Intra-patient Variability of FDG Standardized Uptake Values in Mediastinal Blood Pool, Liver, and Myocardium during R-CHOP Chemotherapy in Patients with Diffuse Large B-cell Lymphoma
verfasst von
Soo Jeong Kim
Hyun Kyung Yi
Chae Hong Lim
Young Seok Cho
Joon Young Choi
Yearn Seong Choe
Kyung-Han Lee
Byung-Tae Kim
Seung Hwan Moon
Publikationsdatum
13.07.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Nuclear Medicine and Molecular Imaging / Ausgabe 4/2016
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-016-0432-y

Weitere Artikel der Ausgabe 4/2016

Nuclear Medicine and Molecular Imaging 4/2016 Zur Ausgabe